LLY

1,008.68

-0.23%↓

JNJ

230.1

+0.62%↑

ABBV

212.81

-0.87%↓

UNH

382.38

-2.45%↓

AZN

187.97

+1.45%↑

LLY

1,008.68

-0.23%↓

JNJ

230.1

+0.62%↑

ABBV

212.81

-0.87%↓

UNH

382.38

-2.45%↓

AZN

187.97

+1.45%↑

LLY

1,008.68

-0.23%↓

JNJ

230.1

+0.62%↑

ABBV

212.81

-0.87%↓

UNH

382.38

-2.45%↓

AZN

187.97

+1.45%↑

LLY

1,008.68

-0.23%↓

JNJ

230.1

+0.62%↑

ABBV

212.81

-0.87%↓

UNH

382.38

-2.45%↓

AZN

187.97

+1.45%↑

LLY

1,008.68

-0.23%↓

JNJ

230.1

+0.62%↑

ABBV

212.81

-0.87%↓

UNH

382.38

-2.45%↓

AZN

187.97

+1.45%↑

Home・Akcijų sąrašas・Kura Oncology Inc

Kura Oncology Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

10.03 10.1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.92

Max

10.04

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.7M -73M
Pardavimai	929K 18M
Pelno marža	-401.495
Darbuotojai	260
EBITDA	7.4M -78M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+205.76% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-31M 813M
Ankstesnė atidarymo kaina	-0.07
Ankstesnė uždarymo kaina	10.03

Naujienos nuotaikos

By Acuity

55%

45%

286 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

5.575 / 6.6 Palaikymas ir pasipriešinimas

Kura Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-19 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026-05-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026-05-19 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026-05-19 22:02; UTC

Uždarbis

ZTO Express (Cayman): Di Xu to Resign From Board

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026-05-19 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026-05-19 21:37; UTC

Uždarbis

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026-05-19 21:31; UTC

Įsigijimai, susijungimai, perėmimai

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026-05-19 21:01; UTC

Uždarbis

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026-05-19 20:58; UTC

Uždarbis

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026-05-19 20:46; UTC

Karštos akcijos

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026-05-19 20:43; UTC

Rinkos pokalbiai

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026-05-19 20:34; UTC

Uždarbis

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q EPS 5c >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q Sales $1.4B >JHX

2026-05-19 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5B

2026-05-19 20:18; UTC

Rinkos pokalbiai

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026-05-19 19:23; UTC

Rinkos pokalbiai

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Akcijų palyginimas

Kainos pokytis

Kura Oncology Inc Prognozė

Kainos tikslas

By TipRanks

205.76% į viršų

12 mėnesių prognozė

Vidutinis 28.13 USD 205.76%

Aukščiausias 40 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Kura Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Kura Oncology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

5.575 / 6.6Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

286 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.